Amgen Inc. (NASDAQ: AMGN) announced the retirement of Chief Financial Officer Peter Griffith and the appointment of Thomas Dittrich as his successor.

Griffith, who has served as executive vice president and CFO since 2020, will retire from his position. Dittrich will return to Amgen as executive vice president on July 1 and assume the CFO role effective September 1, 2026.

"We are grateful to Peter for his leadership and lasting impact on the company," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Peter has helped position Amgen to deliver attractive long-term growth and expand our ability to serve patients in the years ahead."

Dittrich brings more than 30 years of international leadership experience to the role. He previously held senior finance positions at Amgen and most recently served as CFO of Galderma. Prior to that, he served as CFO at both Shire and Sulzer.

During his tenure, Griffith strengthened the company's financial foundation and supported disciplined capital allocation. He will remain with the company through January 2027 to facilitate a transition.

Dittrich will oversee all aspects of Amgen's financial operations upon taking the position. The Thousand Oaks, California-based biotechnology company discovers, develops, manufactures and delivers medicines for various diseases including cancer, inflammatory conditions, rare diseases, heart disease and obesity.